ALK and non-small cell lung carcinoma: Looking forward, more rigorous clinical research is anticipated, particularly the advancement of next-generation ALK inhibitors—such as NVL-655—into later-phase trials, which may further optimize treatment outcomes for this molecular subtype of NSCLC.